NEXI
Price:
$0.35
Market Cap:
$488.13K
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted...[Read more]
Industry
Biotechnology
IPO Date
2021-02-12
Stock Exchange
NASDAQ
Ticker
NEXI
According to NexImmune, Inc.’s latest financial reports and current stock price. The company's current ROE is -526.91%. This represents a change of 235.32% compared to the average of -157.14% of the last 4 quarters.
The mean historical ROE of NexImmune, Inc. over the last ten years is 83.22%. The current -526.91% ROE has changed -733.13% with respect to the historical average. Over the past ten years (40 quarters), NEXI's ROE was at its highest in in the March 2023 quarter at 1.06%. The ROE was at its lowest in in the June 2024 quarter at -252.76%.
Average
83.22%
Median
-90.25%
Minimum
-921.57%
Maximum
1.59%
Discovering the peaks and valleys of NexImmune, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 61.15%
Maximum Annual ROE = 1.59%
Minimum Annual Increase = -2676.78%
Minimum Annual ROE = -921.57%
Year | ROE | Change |
---|---|---|
2023 | -921.57% | -157.89% |
2022 | 1.59% | -2676.78% |
2021 | -61.78% | -130.76% |
2020 | 200.83% | -204.98% |
2019 | -191.31% | 61.15% |
The current ROE of NexImmune, Inc. (NEXI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
202.84%
5-year avg
123.61%
10-year avg
83.22%
NexImmune, Inc.’s ROE is greater than ZyVersa Therapeutics, Inc. (-25512.50%), greater than Palisade Bio, Inc. (-148.31%), greater than Unicycive Therapeutics, Inc. (-374.14%), less than Apexigen, Inc. (48.27%), greater than Immix Biopharma, Inc. (-102.10%), greater than TransCode Therapeutics, Inc. (-649.01%), greater than Landos Biopharma, Inc. (-73.00%), greater than Oncorus, Inc. (-82.19%), greater than Xenetic Biosciences, Inc. (-49.49%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Virios Therapeutics, Inc. (-130.35%), greater than Zura Bio Limited (-39.61%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), less than CNS Pharmaceuticals, Inc. (695.91%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), greater than Mereo BioPharma Group plc (-69.11%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than PDS Biotechnology Corporation (-139.57%), greater than Inozyme Pharma, Inc. (-88.42%), greater than HOOKIPA Pharma Inc. (-49.25%),
Company | ROE | Market cap |
---|---|---|
-25512.50% | $2.65M | |
-148.31% | $3.24M | |
-374.14% | $55.01M | |
48.27% | $9.57M | |
-102.10% | $49.14M | |
-649.01% | $6.64M | |
-73.00% | $71.68M | |
-82.19% | $0 | |
-49.49% | $6.33M | |
2.18% | $941.00 | |
-130.35% | $206.50K | |
-39.61% | $178.25M | |
-173.56% | $100.08K | |
695.91% | $7.15M | |
-398.33% | $2.50M | |
-69.11% | $575.61M | |
-32.76% | $491.80M | |
-139.57% | $78.19M | |
-88.42% | $180.51M | |
-49.25% | $20.76M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NexImmune, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NexImmune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is NexImmune, Inc.'s ROE?
How is the ROE calculated for NexImmune, Inc. (NEXI)?
What is the highest ROE for NexImmune, Inc. (NEXI)?
What is the 3-year average ROE for NexImmune, Inc. (NEXI)?
What is the 5-year average ROE for NexImmune, Inc. (NEXI)?
How does the current ROE for NexImmune, Inc. (NEXI) compare to its historical average?